Patents by Inventor Jeffrey S. Riesmeyer

Jeffrey S. Riesmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC USES OF DULAGLUTIDE
    Publication number: 20240139287
    Abstract: The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk factors without established cardiovascular disease or with established cardiovascular disease comprising administering the glucagon like peptide-1 (GLP-1) receptor agonist dulaglutide.
    Type: Application
    Filed: January 10, 2024
    Publication date: May 2, 2024
    Inventors: Jeffrey S. RIESMEYER, David Bradley WOODWARD
  • Therapeutic uses of dulaglutide
    Patent number: 11890325
    Abstract: The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk factors without established cardiovascular disease or with established cardiovascular disease comprising administering the glucagon like peptide-1 (GLP-1) receptor agonist dulaglutide.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: February 6, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Jeffrey S. Riesmeyer, David Bradley Woodward
  • Therapeutic Uses of Dulaglutide
    Publication number: 20220202908
    Abstract: The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk factors without established cardiovascular disease or with established cardiovascular disease comprising administering the glucagon like peptide-1 (GLP-1) receptor agonist dulaglutide.
    Type: Application
    Filed: November 4, 2019
    Publication date: June 30, 2022
    Inventors: Jeffrey S. Riesmeyer, David Bradley Woodward